Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 344 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Interruption Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Novel Interruption Management Intervention for New Graduate Nurses During Medication Administration

NCT07599215
View directory record Official record
Conditions
Nurses, Education Nursing, Career Mobility, Simulation Based Learning
Interventions
Experimental: Stay S.A.F.E. Interruption Management Education, Medication Safety Education
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Early Phase 1 Interventional Results available

Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration

NCT02389738
View directory record Official record
Conditions
Blood Brain Barrier Defect
Interventions
Regadenoson, Temozolomide, Microdialysis catheter
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

NCT00885326
View directory record Official record
Conditions
Neuroblastoma
Interventions
Bevacizumab, cyclophosphamide, zoledronic acid
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
Up to 30 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

NCT00768755
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
axitinib, chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Atlanta, Georgia • Decatur, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dental Hygiene and Peri-Implant Tissues Homeostasis

NCT03384446
View directory record Official record
Conditions
Peri-Implantitis
Interventions
Tooth-borne treatment, Implant-specific treatment
Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View directory record Official record
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

NCT05415007
View directory record Official record
Conditions
Cancer
Interventions
GOLD Program, Treatment as usual (TAU)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

NCT01787994
View directory record Official record
Conditions
HIV
Interventions
Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional Results available

Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis

NCT03327922
View directory record Official record
Conditions
Interrupted Subdermal Suture
Interventions
Vicryl absorbable suture
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 4, 2026, 11:35 PM EDT
Not yet recruiting No phase listed Observational

Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study

NCT07788040
View directory record Official record
Conditions
Cardiovascular Diseases, Arrhythmias, Cardiac, Atrial Fibrillation
Interventions
Intracardiac Echocardiography Catheter
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional

Restorative Early Sleep Treatment After the Emergency Department

NCT07121270
View directory record Official record
Conditions
Insomnia, Nightmares Associated With Trauma and Stress, Nightmares, PTSD - Post Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia and Nightmares, Sleep Education, Sleep Education enhanced with Nightmare Education
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

NCT00029341
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

NCT06454344
View directory record Official record
Conditions
Adverse Childhood Experiences, Vascular Dilatation, Sleep, Sleep Disturbance, Psychosocial Stressor, Psychological Trauma, Endothelial Dysfunction, Inflammation, Oxidative Stress
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-i)
Behavioral
Lead sponsor
Nathaniel Jenkins
Other
Eligibility
18 Years to 29 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 4, 2026, 11:35 PM EDT
Enrolling by invitation Phase 4 Interventional

Nanozymes in Endodontics

NCT07518901
View directory record Official record
Conditions
Apical Periodontitis, Endodontic Disease, Root Canal Infection
Interventions
Nanozyme treatment, Control (Standard treatment)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia

NCT00507546
View directory record Official record
Conditions
Insomnia, Spinal Cord Injury, Tetraplegia, Sleep Disorders
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

NCT06032546
View directory record Official record
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Interventions
Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

NCT04491084
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
Drug · Biological · Radiation
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Phase 1 Interventional

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

NCT03976050
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HL-085
Drug
Lead sponsor
Shanghai Kechow Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 4, 2026, 11:35 PM EDT